2. Forward Looking Statement
Our commentary and responses to your questions may contain
forward-looking statements, including comments concerning
clinical trials and product development programs, evaluation of
potential opportunities, the level of corporate expenditures,
the assessment of Inovio’s technology by potential corporate
partners, capital market conditions, timing of events, cash
consumption and other subjects. Information concerning
factors that could cause actual results to differ materially from
those set forth in our Annual Report on Form 10-K for the year
ended December 31, 2012, our Form 10-Q for the quarter
ended June 30, 2013 and other regulatory filings from time to
time.
2
5. Products
5
• Targeting cancers
and infectious
diseases
• Multi-billion dollar
healthcare markets
• Lead program for
HPV-caused disease
in phase II
• First efficacy data in
mid-2014
• Multiple clinical
trials in phase I
6. Validation
6
• Advancing
partnering
discussions with
large pharma
• Gates-funded
malaria program
• US gov’t $25M grant
for HIV vaccine
development
• NIH Director:
“Transformational
Research” grant
• Almost $50 million in
non-dilutive grants
in past few years
9. Stimulating the Immune System: A Powerful Legacy
• 1776: concept of
“modern”
vaccination
• Effective vaccines
against 20+
diseases
cowpox anthrax
polio
measles
Edward Jenner Louis Pasteur Maurice Hilleman
9
10. #1 Medical Invention
10
INFANT MORTALITY RATE
WORLDWIDELIFE EXPECTANCY
• Reduced child
mortality
• Increased life span
• Protected billions
from sickness and
death
11. 11
Extending the Legacy
• Concept of
stimulating immune
system as relevant
today as ever
• Can we create 21st
century technology
to fight today’s
cancers &
challenging
infectious diseases?
• Yes!
13. Immune Stimulation in the 21st Century
13
• Synthetic
• Not a
weakened,
killed, or part of
a virus
• Therapeutic
• Not preventive
only
• Universal
• Not protective
against only a
single, matched
strain
14. 14
Inovio’s Synthetic DNA Vaccines
• Contain DNA code for
target disease antigen(s)
• Body produces antigen
• Cannot replicate
• Closest to body’s natural
immune response
• Preventive antibodies
• Therapeutic T-cells
• Formulated in water
• Stable at room temp
Immune response
to last century
conventional vaccine
antibodies
Immune response
to 21st century
DNA vaccine
T-cells
antibodies
15. 15
Novel Consensus Design
• Use gene sequences from
multiple strains or types
of target disease antigen
• Create new antigen DNA
sequence to help the
body recognize:
• “Self” made cancer
cells
• Break tolerance
• Similar but unmatched
strains
• Universal, cross-
strain protection
• Novel DNA sequences
patentable
Differentiate
cancer cells
from “self”
Multi-strain
protection within
Pathogen families
New synthetic consensus sequence
Multiple unique strains
BreakTolerance Universal Protection
16. Efficient DNA Vaccine Manufacturing
16
• DNA plasmid
production
• Bacterial
fermentation
process
• Efficient, fast, cost
effective, scalable
17. DNA Delivery: Electroporation
Electric fields appliedVaccine injection
• Overcome two
decade hurdle of
DNA delivery
• Millisecond
electric pulses
create pores in cells
• Increase vaccine
uptake 1000X
• Enables cells to
produce target
antigen
• Widest and deepest
global patent estate
17
Cellular vaccine uptakeCell produces coded antigen
19. Functional T-Cell Responses
• Highest magnitude
of T-cell responses
• 83% response rate
in highest dose
group
• 92% of responders
showed 9 month
durability
• 91% of responders
showed killing
effect against target
cells
• HIV study: 89%
response rate with
robust T-cells
19
20. Universal Immune Responses
20
• Protective HAI titers
in humans against 9
unmatched strains
of H1N1 flu from
last 100 years
• Strong HAI titers in
humans against 6
unmatched strains
of deadly H5N1 flu
• Protection against
newly emergent,
pandemic-potential
H7N9 influenza in
mice challenge
study
Conventional vaccine:
single matched strain
only
DNA vaccine:
multiple
unmatched strains
21. Preclinical Phase I Phase II
Product Pipeline
indication milestone
INTERNALLY FUNDED EXTERNALLYFUNDED
Cervical dysplasia THERAPEUTIC
HIV PREVENTIVE/THERAPEUTIC
influenza PREVENTIVE
Hepatitis C THERAPEUTIC
Malaria PREVENTIVE
Mid-2014
Phase II study data
2013
Initiate PENNVAX-GP Phase I study
2013
Phase I data reported
4Q 2013
Initiate Phase I/IIa
2014
Initiate Phase I/IIa
22. Inovio’s
Lead Program
• VGX-3100: therapeutic vaccine
• HPV-caused pre-cancers &
cancers
• Phase II
• First efficacy data: mid-2014
22
23. 23
Cervical Cancer 12,357 new cases
3,909 deaths
CIN 2/3 dysplasia 300-400K new cases
CIN 1 dysplasia 1.4M new cases
Head & neck cancer (HPV Related) 8,380 new cases
7,922 deaths (oropharyngeal
only)
Anogenital cancers (HPV related )
- Excludingcervical
7,931 new cases
2,396 deaths
U.S. Market opportunity ~ 70% of high risk cervical pre-cancers & cancers
caused by HPV Type 16 and 18
Therapeutic HPV
24. VGX-3100
Therapeutic HPV
• Diseases caused by HPV Type
16 and 18; Target antigens:
E6 and E7
• 18 “healthy” patients with
prior CIN 2/3 dyplasia
• Robust immediate
T-cell response, average
across dose groups/78%
• Dose response
• 92% of responders showed
9 month durability
• 91% with killing effect
• Safe & well tolerated
24
Phase I Trial
Results
25. Next steps
Therapeutic HPV
Top-line efficacy data expected mid-2014
• Study protocol: minimum 148
patients with CIN 2/3
• Enrollment completed
• Randomized, double-blinded,
placebo controlled
• More than 25 sites in 7 countries
• Primary endpoint: lesion
clearance within 9 months
25
Phase IITrial
27. power of
our people
• Management
• Board of Directors
• Scientific Advisory Board
27
28. Management
anthrax
polio
cowpox
Louis Pasteur
J.Joseph Kim, PhD
President & CEO
• Decades of biotechnology/pharma
management
• Ex-Merck: hepatitis A and B vaccines
manufacturing; HIV vaccine (Ad5) R&D
Niranjan Y. Sardesai, PhD
COO
• Extensive biotech management and product
development experience
• Led development of diagnostics for
mesothelioma, bladder cancer, and ovarian
cancer for Fujirebio Diagnostics
Peter Kies
CFO
• Ex-Ernst & Young
• Experience with growth companies
Mark L. Bagarazzi, MD
CMO
• Clinical research experience incl. Merck
• Led clinical/regulatory for shingles and
rotavirus vaccines; DNA vaccine expert
28
29. Board of Directors
anthrax
polio
cowpox
Louis Pasteur
Simon X. Benito
• Former Senior Vice President,
Merck Vaccine Division
Angel Cabrera, PhD
• President, George Mason University
• Former President, Thunderbird School of
Global Management
J.Joseph Kim, PhD
• President & CEO, Inovio
Adel Mahmoud, PhD
• Professor, Princeton University
• Former President, Merck Vaccines
• Responsible for Gardasil®, Zostavax®,
Proquad® and Rotateq®
Avtar Dhillon, MD
Chairman, BOD
• Former President & CEO,
Inovio Biomedical
Morton Collins, PhD
• General Partner, Battelle Ventures and
Innovations Valley Partners
29
30. Scientific Advisory Board
anthrax
polio
cowpox
Louis Pasteur
Thomas S. Edgington, MD
• Founded multiple biotech companies;
extensively published
• Emeritus Professor, Scripps
Research Institute
Anthony W. Ford-Hutchinson, PhD
• Former SVP, Vaccines R&D, Merck
• Oversaw development: Singulair®, Januvia®,
Gardasil®, Zostavax®, Proquad® and Rotateq®
Stanley A. Plotkin, MD
• Developed rubella and rabies vaccines
• Oversaw Sanofi flu vaccine
• Emeritus Professor, Wistar Institute &
University of Pennsylvania
David B. Weiner, PhD
Chairman
•“Father of DNA vaccines”
• Dept. of Pathology & Laboratory Medicine,
University of Pennsylvania
Philip Greenberg, MD
• Expert in T-cell immunology
• Head, Immunology Program, Fred
Hutchinson Cancer Research Center
30
